Stock Market Reviews

APLT (Applied Therapeutics, Inc.) News

Get the latest news, insights, and market updates on APLT (Applied Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
  CAMBRIDGE, England & DETROIT, February 03, 2026--Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical company.
  Feb 3, 2026 - $APLT
• Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
  CAMBRIDGE, England & DETROIT, January 30, 2026--Cycle Group Holdings Limited ("Cycle" or "Parent") today announces that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation ("Applied") for (i) $0.088 per share, net to the seller in cash, without interest, plus (i
  Jan 30, 2026 - $APLT
• Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
  CAMBRIDGE, England & DETROIT, January 29, 2026--Cycle Group Holdings Limited ("Cycle" or "Parent") today announces that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation ("Applied") for (i) $0.088 per share, net to the seller in cash, without interest, plus (i
  Jan 29, 2026 - $APLT
• Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
  NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. (“Purchaser”), an indirect wholly owned subsidiary of Cycle Group Holdings Limited (“Cycle”). January 29, 2026 Dear Applied Therapeutics Stockholders, As announced on Decemb
  Jan 29, 2026 - $APLT
• Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
  CAMBRIDGE, England & DETROIT, January 28, 2026--Cycle Group Holdings Limited ("Cycle" or "Parent") today announces that AT2B, Inc., a Delaware corporation ("Purchaser") and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation ("Applied") for (i) $0.088 per share, net to the seller in cash, without interest, plus (i
  Jan 28, 2026 - $APLT
• BC-Most Active Stocks
  td class="col-issue">Hycroft Mining Holding Corp.
  Dec 24, 2025 - $APLT
• Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now
  Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
  Dec 16, 2025 - $APLT
• Cycle Pharmaceuticals to Acquire Applied Therapeutics
  Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseasesNEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced a definitive agreement for Cycle Group Holdings Limited (“Cycle”) to acquire Applied Therapeutics. App
  Dec 11, 2025 - $APLT
• Applied Therapeutics (APLT) Upgraded to Buy: Here's Why
  Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Nov 27, 2025 - $APLT
• Applied Therapeutics Announces Corporate Updates
  NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that Applied Therapeutics’ Board of Directors (the “Board”) has initiated a process to explore strategic alternatives for the Company. The Board intends to evaluate a broad range of opportunities to maximize shareholder value. Strategic alternatives under consideration m
  Nov 20, 2025 - $APLT